Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Get the latest updates from Investor Update directly as they happen.
Follow now 353 followers
Last updated 2 days ago
2 days ago
Group sales grew by 7%1 at constant exchange rates (CER; 2% in...
5 days ago
Roche will publish its Sales for the 3rd Quarter of 2025 prior...
5 days ago
Roche will publish its Sales for the 3rd Quarter of 2025 prior...
5 days ago
Tecentriq reduced the risk of death by 41% and the risk of...
5 days ago
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as...
7 days ago
Giredestrant plus everolimus reduced the risk of disease progression or death by...
7 days ago
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving...
8 days ago
Positive recommendation based on phase II NOBILITY and phase III REGENCY data...
9 days ago
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial...
11 days ago
We are pleased to invite investors and analysts to participate in our...
12 days ago
Rules out Alzheimer’s pathology in early stages to enhance diagnostic pathway efficiencyProvides...
12 days ago
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...